BioLineRx (BLRX)
(Delayed Data from NSDQ)
$1.11 USD
+0.08 (7.77%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BLRX 1.11 +0.08(7.77%)
Will BLRX be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for BLRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for BLRX
BLRX Stock Earnings: BioLine Rx Beats EPS for Q4 2023
Buy Rating Affirmed for BioLineRx: Strong Financials and Expanding Market Presence Fuel Analyst Optimism
BioLineRx Ltd. (BLRX) Q4 2023 Earnings Call Transcript
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GOEV, NBSE and FLGC among pre-market losers